Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07470840) titled 'SBRT, Anlotinib and Benmelstobart for RCC' on March 6.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Fujian Cancer Hospital
Condition:
Locally Advanced or Metastatic Renal Cell Carcinoma
Intervention:
Radiation: Stereotactic Body Radiation Therapy (SBRT)
Drug: Anlotinib
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: February 1, 2027
Target Sample Size: 27
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/study/NCT07...